ANAB
AnaptysBio, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.3% ·
share flow +8.6% ·
net new positions +5.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 86 | +7 | 13.42M | $905.56M | +13 | −6 |
| Q1 2026 | 82 | +8 | 12.40M | $687.67M | +10 | −2 |
| Q4 2025 | 74 | -1 | 13.98M | $677.76M | n/a | −1 |
| Q3 2025 | 20 | +1 | 11.93M | $365.35M | +1 | n/a |
| Q2 2025 | 16 | 0 | 9.08M | $201.48M | +1 | −1 |
| Q1 2025 | 13 | +2 | 6.02M | $111.87M | +2 | n/a |
| Q4 2024 | 11 | -2 | 3.90M | $51.60M | n/a | −2 |
| Q3 2024 | 12 | +2 | 2.80M | $93.85M | +2 | n/a |
| Q2 2024 | 10 | n/a | 1.82M | $45.55M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 2.27M | -8.5% | $69.37M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 1.72M | -3.6% | $52.74M | 0.0% | ▼ Trim | 2 | SEC ↗ ×12 |
| 3 | Morgan Stanley ✦ | 1.56M | n/a | $47.65M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 4 | Millennium Management ✦ | 1.52M | +646.4% | $46.52M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 5 | The Vanguard Group ✦ (passive) | 1.48M | -3.9% | $45.23M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 6 | State Street Global Advisors ✦ (passive) | 873.43K | +6.4% | $26.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 473.63K | +2.2% | $14.50M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Arrowstreet Capital ✦ | 370.46K | +145.7% | $11.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 349.36K | +211.0% | $10.70M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Goldman Sachs Group ✦ | 329.82K | n/a | $10.10M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | T. Rowe Price ✦ | 299.31K | -55.5% | $9.17M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | Two Sigma Investments ✦ | 256.42K | +10.8% | $7.85M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 123.30K | -53.1% | $3.78M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Wellington Management ✦ | 66.73K | -16.8% | $2.04M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 15 | Fisher Asset Management ✦ | 58.88K | 0.0% | $1.80M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Marshall Wace ✦ | 54.42K | New | $1.67M | 0.0% | New | 1 | SEC ↗ ×2 |
| 17 | Fidelity (FMR) ✦ | 53.16K | -26.3% | $1.63M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 18 | JPMorgan Chase ✦ | 29.70K | n/a | $909,538 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 19 | Citadel Advisors ✦ | 26.48K | -77.6% | $810,818 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 26.17K | -5.6% | $801,449 | 0.0% | ▼ Trim | 5 | SEC ↗ ×5 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $1.67M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 205 holders, 28.23M shares, $1.54B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 5.00K sh · $249,372
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology